← Back to screener

BridgeBio Pharma, Inc. BBIO

Rank #2018 · Nasdaq · $14.7B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
36.1
P/E
-22.5
P/B
-10.00
ROE
44.5%
Op. Margin
-6528.8%
Debt Ratio
-162%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -22.5x, P/B -10.00x. Ranks in the top 88% of the universe.

Profitability ★★☆☆☆
Average

ROE 44.5%. Ranks in the top 53% of the universe.

Safety ★★★★★
Excellent

Debt ratio -162%. Ranks in the top 5% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 88.0% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2019$0.0B$-0.0B$-0.0B$0.0B-108.1588
2020$0.0B$-0.2B$-0.2B$0.4B-452.838
2021$0.0B$-0.3B$-0.3B$0.1B-656.41029
2022$0.0B$-0.5B$-0.5B$-0.9B-5752.0-216
2023$0.1B$-0.6B$-0.6B$-1.3B-827.1-149
2024$0.1B$-0.5B$-0.5B$-1.4B-659.6-139
2025$0.0B$-0.6B$-0.7B$-1.5B-6528.8-162

← See the full screener